(Q52041442)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11978502%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

title

The application of population pharmacokinetic modeling to individualized antibiotic therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11978502%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

0 references

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11978502%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

author name string

Alexander A Vinks

series ordinal

1

1 reference

20 April 2018

http://europepmc.org/abstract/MED/11978502

publication date

1 April 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11978502%20AND%20SRC:MED&resulttype=core&format=json

International Journal of Antimicrobial Agents

10 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11978502%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

volume

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11978502%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11978502%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

page(s)

313-322

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11978502%20AND%20SRC:MED&resulttype=core&format=json

Relevance of the application of pharmacokinetic-pharmacodynamic modelling concepts in drug development. The "wooden shoe' paradigm

10 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900023-7

7 January 2021

Model-based, goal-oriented, individualised drug therapy. Linkage of population modelling, new 'multiple model' dosage design, bayesian feedback and individualised target goals

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900023-7

7 January 2021

Alternative approaches to estimation of population pharmacokinetic parameters: comparison with the nonlinear mixed-effect model

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900023-7

7 January 2021

Forecasting individual pharmacokinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900023-7

7 January 2021

Software for population pharmacokinetics and pharmacodynamics

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900023-7

7 January 2021

NONMEM and NPEM2 population modeling: a comparison using tobramycin data in neonates

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900023-7

7 January 2021

Tobramycin population pharmacokinetics in neonates.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900023-7

7 January 2021

Clinical pharmacokinetics in the 21st century. Does the evidence support definitive outcomes?

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900023-7

7 January 2021

Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900023-7

7 January 2021

Drug dosage in patients during continuous renal replacement therapy. Pharmacokinetic and therapeutic considerations

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900023-7

7 January 2021

Dosage adjustment for ceftazidime in patients with impaired renal function

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900023-7

7 January 2021

Population modelling in drug development

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900023-7

7 January 2021

The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900023-7

7 January 2021

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900023-7

7 January 2021

Basis of anti-infective therapy: pharmacokinetic-pharmacodynamic criteria and methodology for dual dosage individualisation

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900023-7

7 January 2021

Is continuous infusion of beta-lactam antibiotics worthwhile?--efficacy and pharmacokinetic considerations

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900023-7

7 January 2021

Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900023-7

7 January 2021

A pharmacodynamic model for the activity of antibiotics against microorganisms under nonsaturable conditions.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900023-7

7 January 2021

Pharmacokinetic-pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900023-7

7 January 2021

Pharmacokinetic optimisation of antibacterial treatment in patients with cystic fibrosis. Current practice and suggestions for future directions.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900023-7

7 January 2021

Pharmacokinetic modelling of intravenous tobramycin in adolescent and adult patients with cystic fibrosis using the nonparametric expectation maximization (NPEM) algorithm

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900023-7

7 January 2021

Pharmacokinetics and dose requirements of vancomycin in neonates

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900023-7

7 January 2021

Population pharmacokinetic study of teicoplanin in severely neutropenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900023-7

7 January 2021

Pharmacokinetics and tissue concentrations of cefuroxime

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900023-7

7 January 2021

Determination of plasma and renal clearance of cefuroxime and its pharmokinetics in renal insufficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900023-7

7 January 2021

Population pharmacokinetics of ceftazidime in cystic fibrosis patients analyzed by using a nonparametric algorithm and optimal sampling strategy

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900023-7

7 January 2021

Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900023-7

7 January 2021

Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900023-7

7 January 2021

10.1016/S0924-8579(02)00023-7

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11978502%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

1 reference